23 LifeScience Companies Changing the World : BioPharma APAC 2023 Outlook
03 January 2023 | Tuesday | News
The Outlook for 2023 and Beyond 23 giants from the world of biotech and life sciences offer their vision for the future of the industry over the next decade.
Image Source : Public Domain
These companies are often involved in the research, development, and production of pharmaceuticals, medical devices, and other health-related products.
- Roche - $64.3 billion
- Johnson & Johnson - $82.1 billion
- Pfizer - $53.7 billion
- Novartis - $47.5 billion
- Merck & Co. - $45.8 billion
- AstraZeneca - $26.8 billion
- Sanofi - $40.8 billion
- GlaxoSmithKline - $43.7 billion
- AbbVie - $45.6 billion
- Amgen - $23.4 billion
- Bristol-Myers Squibb - $26.8 billion
- Eli Lilly and Company - $22.4 billion
- Takeda Pharmaceutical - $17.9 billion
- Teva Pharmaceutical Industries - $16.2 billion
- Thermo Fisher Scientific - $25.3 billion
- Biogen - $11.4 billion
- Celgene - $11.4 billion
- Gilead Sciences - $22.2 billion
- Regeneron Pharmaceuticals - $7.1 billion
- Vertex Pharmaceuticals - $6.0 billion
- Astellas Pharma - $17.1 billion
- Boehringer Ingelheim - $17.8 billion
- Merck KGaA - $16.1 billion
Please note that these figures are from 2021 and may not reflect the current revenue of these companies. Additionally, the rankings may vary depending on the source and the criteria used to evaluate the companies.
Most Read
- 25 Biopharma Leaders Shaping a Sustainable 2025: Innovation Meets Environmental Responsibility
- 25 Leading AI Companies to Watch in 2025: Transforming Drug Discovery and Precision Medicine
- Mr. Brendan O’Callaghan Discusses Sanofi’s Singapore Modulus Facility: Advancing Biopharma Manufacturing and Pandemic Preparedness
- Shaping the Future of PCV Care: Insights from Roche’s Stefan Scheidl on the SALWEEN Trial
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Shaping a Health Innovation Hub: Alessandro Falcone Reflects on JLABS Singapore’s Milestone Year and Future Goals
Bio Jobs
- Avance Clinical Appoints Jessica Han as Director of Asian Operations, Strengthening Commitment to the Asian Market
- Bristol Myers Squibb Employees Cycle Coast-to-Coast to Raise $1 Million for Cancer Research
- Pfizer Australia Commits $150M to Upgrade Melbourne Facility, Bolstering Global Fight Against Antimicrobial Resistance
- SMi Systems Appoints Dr. Stefan Hamill as Vice President of Strategy to Drive Commercialisation and Growth
- Thermo Fisher Scientific Appoints William Hung as Senior Director and General Manager for Taiwan
- Cytiva Appoints Industry Veteran Pierre-Alain Ruffieux as Chief Operating Officer
News
